{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(7)"],"submitter":["He C"],"pubmed_abstract":["Chimeric antigen receptor (CAR) T-cell therapy is a promising approach in treating solid tumors but the therapeutic effect is limited. Prostate cancer is a typical solid malignancy with invasive property and a highly immunosuppressive microenvironment. Ligands for the NKG2D receptor are primarily expressed on many cancer cells, including prostate cancer. In this study, we utilized NKG2D-based CAR to treat prostate cancer, and improved the therapeutic effect by co-expression of IL-7. The results showed that NKG2D-CAR T cells performed significantly increased cytotoxicity against prostate cancer compared to non-transduced T cells in vitro and in vivo. Moreover, the introduction of the <i>IL-7</i> gene into the NKG2D-CAR backbone enhanced the production of IL-7 in an antigen-dependent manner."],"journal":["Cancers"],"pagination":["E1969"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7409228"],"repository":["biostudies-literature"],"pubmed_title":["Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion."],"pmcid":["PMC7409228"],"pubmed_authors":["He C","Farooq MA","Yao J","Li Z","Tao L","Du B","Liu M","Jiang W","Zhang H","Zhang L","Zhou Y","Ajmal I"],"additional_accession":[]},"is_claimable":false,"name":"Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion.","description":"Chimeric antigen receptor (CAR) T-cell therapy is a promising approach in treating solid tumors but the therapeutic effect is limited. Prostate cancer is a typical solid malignancy with invasive property and a highly immunosuppressive microenvironment. Ligands for the NKG2D receptor are primarily expressed on many cancer cells, including prostate cancer. In this study, we utilized NKG2D-based CAR to treat prostate cancer, and improved the therapeutic effect by co-expression of IL-7. The results showed that NKG2D-CAR T cells performed significantly increased cytotoxicity against prostate cancer compared to non-transduced T cells in vitro and in vivo. Moreover, the introduction of the <i>IL-7</i> gene into the NKG2D-CAR backbone enhanced the production of IL-7 in an antigen-dependent manner.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2026-05-04T04:27:27.716Z","creation":"2020-08-30T07:19:18Z"},"accession":"S-EPMC7409228","cross_references":{"pubmed":["32698361"],"doi":["10.3390/cancers12071969"]}}